REGULATED PRESS RELEASE
News
-
-
REGULATED PRESS RELEASE
AMOEBA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
AMOÉBA confirme son éligibilité au dispositif PEA-PME pour l'année 2024, permettant l'intégration de ses actions dans les portefeuilles PEA PME. La biotech se concentre sur le traitement du risque microbiologique dans les secteurs de l'eau, de la protection des plantes et de la santé -
REGULATED PRESS RELEASE
AMOEBA : Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 décembre 2023
Déclaration du nombre total de droits de vote et du nombre d’actions composant le capital au 31 décembre 2023 pour Amoéba, société cotée sur Euronext Growth. Ambition de devenir un acteur majeur du traitement du risque microbiologique dans les secteurs de l’eau, de la protection des plantes et de la santé. Commercialisation de produits biocontrôle prévue dès 2025 -
REGULATED PRESS RELEASE
Le Groupe PLC, soutenu par l'IDI et Stags, élargit son portefeuille de galéniques avec l’acquisition de Creapharm Cosmetics
Le Groupe PLC acquiert Creapharm Cosmetics, CDMO spécialiste du façonnage de produits cosmétiques. Creapharm permet à PLC de diversifier son offre et de renforcer sa position sur le marché des CDMO. L'acquisition inclut le réinvestissement de la famille Placet -
PRESS RELEASE
Argo Blockchain PLC Announces December Update/Management Change/Share Allotment
Argo Blockchain plc, a global leader in cryptocurrency mining, has reported a 4% increase in daily Bitcoin production in December 2023, along with a 25% rise in mining revenue compared to the previous month. The company also disclosed changes in management and share allotment, as well as the grant of equity awards. Argo Blockchain plc is a dual-listed blockchain technology company focusing on large-scale cryptocurrency mining and sustainability. For more information, visit www.argoblockchain.com. -
PRESS RELEASE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. -
PRESS RELEASE
Smart IMS Strengthens Executive Team, Insurtech Leader Anil Chitale Appointed as Managing Director
Smart IMS, a leading technology service and solutions provider, has appointed Anil Chitale as the Managing Director. With over 35 years of experience in the U.S. Insurance industry, Anil's addition to the executive team is expected to further strengthen the company's offerings in the Insurance space. The company aims to leverage Anil's expertise to enhance its business growth and provide world-class technology solutions to its clients in the fast-changing technology and regulatory environment. Smart IMS is headquartered in Plainsboro, New Jersey and offers a wide range of global technology solutions including Application & Infrastructure Management services, Unified Communications, and Life Sciences and Insurance services. -
PRESS RELEASE
Guanajuato Silver Arranges Debt Settlement
Guanajuato Silver Company Ltd. has announced a debt settlement arrangement to settle outstanding liabilities with the issuance of common shares. The settlement includes the issuance of shares to suppliers and senior management, with the intention of relying on exemptions from certain requirements. The company's material change report will be filed in connection with this announcement, and the debt settlement is subject to TSX-V acceptance and statutory hold period. Guanajuato Silver is a growing precious metals producer in Mexico, and the news release contains forward-looking statements and information. -
PRESS RELEASE
Vicinity Motor Corp. Issues DSUs
Vicinity Motor Corp. has announced the granting of Deferred Share Units (DSUs) in connection with Directors Remuneration for the fourth quarter of 2023. Certain Eligible Directors have requested that their respective director's remuneration for the calendar year 2023 be paid in DSUs. Vicinity Motor Corp. is a North American supplier of electric vehicles for both public and commercial enterprise use, leveraging a dealer network and close relationships with world-class manufacturing partners to supply its flagship electric, CNG and clean-diesel Vicinity buses, as well as the VMC 1200 electric truck to the transit and industrial markets. -
PRESS RELEASE
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted 7,500 restricted stock units (RSUs) to a new employee, with vesting over three years. The RSUs were approved by the Compensation Committee of Jaguar's Board and are subject to the employee's continued service. Jaguar Health is a pharmaceutical company focused on developing prescription medicines derived from plants for gastrointestinal distress.
